dipyridamole has been researched along with Cross Infection in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Cross Infection: Any infection which a patient contracts in a health-care institution.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Tonew, M | 1 |
Tonew, E | 1 |
Linde, P | 1 |
Stelzner, A | 1 |
1 other study available for dipyridamole and Cross Infection
Article | Year |
---|---|
Dipyridamole (Curantyl, Antistenocardin) failed to induce interferon (IFN) in man.
Topics: Cells, Cultured; Cross Infection; Dipyridamole; Humans; Interferons; Vesicular stomatitis Indiana vi | 1989 |